Genomics

Element Biosciences Becomes the Newest Member of 10x Genomics’ CPP

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI System and 10x Genomics’ single cell technologies.

10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, chemistry, and software to give single cell and spatial views of biology at a scale and efficiency that is unprecedented. The combination of the AVITI System’s performance, cost, and flexibility with 10x Genomics’ leading single cell assays provides customers more access and choice for their biological research.

“We are excited about the partnership we’ve established with 10x Genomics and our new status as a validated CPP member,” said Shawn Levy, Senior Vice President of Applications and Scientific Affairs, Element Biosciences. “As one of the most exciting new areas in NGS, we believe this will help bring 10x Genomics’ and Element Biosciences’ customers together for our combined performance and cost advantages in single cell and spatial analysis.”

“At 10x Genomics, part of our commitment to supporting our customers with single cell and spatial analysis is ensuring they have access to advanced sequencing solutions through rigorous validation,” said Brad Crutchfield, Chief Commercial Officer, 10x Genomics. “We are excited to certify Element through our Compatible Partner Program and provide our customers with more ways to adopt single cell and spatial analysis to enhance their research and fuel scientific discoveries.”

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.

Related posts

OriCiro Announces B2 Financing to Advance Cell-Free DNA Technology

PR Newswire

Cergentis introduces in-house solution for CHO clone selection

PR Newswire

Scribe Therapeutics Announces Research Collaboration with Sanofi

Business Wire